SIGN UP
LOG IN
News
VTGN
4.750
-2.86%
-0.140
Weekly Report: what happened at VTGN last week (0408-0412)?
Weekly Report · 22h ago
Weekly Report: what happened at VTGN last week (0401-0405)?
Weekly Report · 04/08 09:00
Vistagen Initiates PALISADE-3 Phase 3 Study Of Fasedienol For The Acute Treatment Of Social Anxiety Disorder Following Results Of PALISADE-2
Key study underway in registration-directed PALISADE Phase 3 program for fasedienol in social anxiety disorder Social anxiety disorder affects over 25 million Americans. Vistagen has enrolled the first patient in its PALISade-3 Phase 3 trial of fasesienol for the acute treatment of sad. The U.S. FDA has granted Fast Track designation for the investigation of fasediensol for sAD.
Benzinga · 04/01 12:31
VISTAGEN THERAPEUTICS INC: PLANS TO INITIATE PALISADE-4, WHICH WILL BE A REPLICATE OF PALISADE-3, DURING SECOND HALF OF 2024
Reuters · 04/01 12:30
Weekly Report: what happened at VTGN last week (0325-0329)?
Weekly Report · 04/01 09:00
Weekly Report: what happened at VTGN last week (0318-0322)?
Weekly Report · 03/25 09:00
Vistagen Therapeutics: Initial Analysis Of Fasedienol Points To Bullish
Vistagen Therapeutics has a strong pipeline of candidates for social anxiety disorder, major depressive disorder, vasomotor symptoms, and more. The company's lead program, Fasedienol, is a neuroactive nasal spray that could be a breakthrough in the management of SAD. Vistagen is a biopharma developing drugs for mental health disorders. I believe VTGN offers an enticing risk-reward at this time.
Seeking Alpha · 03/21 01:01
Weekly Report: what happened at VTGN last week (0311-0315)?
Weekly Report · 03/18 09:00
Why VistaGen Therapeutics Is A Buy: Fasedienol Potential For Anxiety Treatments
Seeking Alpha · 03/17 07:07
Weekly Report: what happened at VTGN last week (0304-0308)?
Weekly Report · 03/11 09:00
Weekly Report: what happened at VTGN last week (0226-0301)?
Weekly Report · 03/04 09:00
Weekly Report: what happened at VTGN last week (0219-0223)?
Weekly Report · 02/26 09:00
Does VistaGen Therapeutics, Inc. (VTGN) Have the Potential to Rally 160% as Wall Street Analysts Expect?
NASDAQ · 02/21 14:55
Weekly Report: what happened at VTGN last week (0212-0216)?
Weekly Report · 02/19 09:00
Buy Rating Affirmed for VistaGen: Promising Clinical Results and Strong Financial Outlook
TipRanks · 02/15 15:45
Vistagen Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Vistagen Therapeutics Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 22 cents per share. Revenue rose 128.6% to $411.40 million from a year ago. Average analyst rating on the shares is "strong buy"
Reuters · 02/13 23:32
Vistagen Therapeutics files for $350M mixed shelf
Vistagen Therapeutics files for $350M mixed shelf Feb. 13, 2024. The company filed a prospectus related to a mixed shelf offering of up to $350 million. Vistagen's stock is down 2.7% in the last week.
Seeking Alpha · 02/13 22:04
VistaGen Therapeutics Q3 EPS $(0.22) Beats $(0.30) Estimate, Sales $411.40K Miss $544.50K Estimate
VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $0.22 per share. The company beat the analyst consensus estimate by 26.67%. The company reported quarterly sales of $411.40 thousand but missed the estimate by 24.44 percent.
Benzinga · 02/13 21:31
Recap: Vistagen Therapeutics Q3 Earnings
Vistagen Therapeutics reported its Q3 earnings on February 13, 2024. The company beat estimates by 26.67%. The company's revenue was up $231 thousand from the same period last year. Last quarter the company beat on EPS by $0.02 and the share price dropped 11.07%.
Benzinga · 02/13 21:25
Press Release: Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update
Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update Fasedienol PALISADE Phase 3 program for the acute treatment of social anxiety disorder remains on track. Vistagen is a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and neurological disorders.
Dow Jones · 02/13 21:20
More
Webull provides a variety of real-time VTGN stock news. You can receive the latest news about Vistagen Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About VTGN
Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company focuses on transforming the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. It is advancing therapeutics for treatment of anxiety, depression, and multiple CNS disorders. Its pipeline includes six clinical-stage product candidates, including fasedienol (PH94B), itruvone (PH10), PH15, PH80, and PH284, each an investigational agent belonging to a new class of drugs known as pherines, as well as AV-101, which is an oral antagonist of the N-methyl-D-aspartate receptor (NMDAR). Pherines, which are administered as low-dose nasal sprays, are designed with a rapid-onset mechanism of action that activates chemosensory neurons in the nasal cavity and can impact key neural circuits in the brain without systemic uptake or direct activity on CNS neurons in the brain. PH94B is a synthetic investigational pherine from the androstane family.